Please use this identifier to cite or link to this item: https://hdl.handle.net/10923/23945
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAGARWAL, NEERAJ-
dc.contributor.authorAZAD, ARUN-
dc.contributor.authorSHORE, NEAL D-
dc.contributor.authorCARLES, JOAN-
dc.contributor.authorAndré Poisl Fay-
dc.contributor.authorDUNSHEE, CURTIS-
dc.contributor.authorKARSH, LAWRENCE IVAN-
dc.contributor.authorPACCAGNELLA, MARIA LUISA-
dc.contributor.authorSANTO, NICOLA DI-
dc.contributor.authorELMELIEGY, MOHAMED-
dc.contributor.authorLIN, XUN-
dc.contributor.authorCZIBERE, AKOS-
dc.contributor.authorFIZAZI, KARIM-
dc.date.accessioned2023-03-29T18:13:06Z-
dc.date.available2023-03-29T18:13:06Z-
dc.date.issued2022-
dc.identifier.issn1479-6694-
dc.identifier.urihttps://hdl.handle.net/10923/23945-
dc.language.isoen-
dc.relation.ispartofFuture Oncology-
dc.rightsopenAccess-
dc.titlePlain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer-
dc.typeArticle-
dc.date.updated2023-03-29T18:13:05Z-
dc.identifier.doiDOI:10.2217/fon-2022-0389-
dc.jtitleFuture Oncology-
dc.volume18-
dc.issue27-
dc.spage2979-
dc.epage2986-
Appears in Collections:Artigo de Periódico



All Items in PUCRS Repository are protected by copyright, with all rights reserved, and are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Read more.